NovoCure (FRA:038) Debt-to-Equity : 1.65 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is NovoCure Debt-to-Equity?

NovoCure's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.0 Mil. NovoCure's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €546.8 Mil. NovoCure's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €332.4 Mil. NovoCure's debt to equity for the quarter that ended in Dec. 2023 was 1.64.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NovoCure's Debt-to-Equity or its related term are showing as below:

FRA:038' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09 Med: 0.93 Max: 1.65
Current: 1.65

During the past 11 years, the highest Debt-to-Equity Ratio of NovoCure was 1.65. The lowest was 0.09. And the median was 0.93.

FRA:038's Debt-to-Equity is ranked worse than
94.94% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FRA:038: 1.65

NovoCure Debt-to-Equity Historical Data

The historical data trend for NovoCure's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Debt-to-Equity Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.75

0.93

1.40

1.32

1.65

NovoCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.32	1.36	1.41	1.50	1.65

Competitive Comparison of NovoCure's Debt-to-Equity

For the Medical Devices subindustry, NovoCure's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NovoCure's Debt-to-Equity falls into.

NovoCure Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NovoCure's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	546.754)	/	332.409
	=	1.64

NovoCure's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	546.754)	/	332.409
	=	1.64

NovoCure (FRA:038) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NovoCure Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NovoCure's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NovoCure (FRA:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NVCR:USA 038:Germany

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (FRA:038) Headlines

No Headlines